CABG Surgery (Coronary Artery Bypass Grafting) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Coronary artery bypass grafting (CABG), commonly called bypass surgery or open-heart surgery, is a surgical procedure that creates new routes for blood to flow around blocked or narrowed coronary arteries to restore adequate oxygen supply to the heart muscle (myocardium). It is the most commonly performed cardiac surgical procedure globally, with over 300,000 operations performed annually in the United States alone, and is the established gold-standard treatment for complex multi-vessel coronary artery disease (CAD) and left main coronary artery disease.

During conventional CABG, the patient is placed on cardiopulmonary bypass (the heart-lung machine), the heart is stopped with cardioplegia solution, and the surgeon attaches conduit vessels (grafts) from points on the aorta or systemic circulation to the coronary arteries beyond the blockages — the bypass routes divert blood around the obstructions. Grafts are harvested from the left internal mammary artery (LIMA — the gold standard graft, with 90% patency at 10 years), the right internal mammary artery (RIMA), the radial artery from the forearm, or the long saphenous vein from the leg. Multiple bypasses (double, triple, quadruple, or quintuple) are performed as required by the extent of disease.

The typical CABG procedure takes three to six hours and requires a median sternotomy (splitting of the breastbone), five to seven days in hospital, and three to four months for full recovery. Compared with percutaneous coronary intervention (PCI/stenting), CABG provides superior long-term outcomes in patients with three-vessel coronary disease, left main disease, and diabetes with multi-vessel disease — indications where the additional short-term procedural risk of surgery is justified by substantially better long-term survival, freedom from repeat revascularisation, and quality of life.

CABG treats severe coronary artery disease (CAD) — atherosclerotic narrowing or blockage of the coronary arteries — causing refractory angina (chest pain on exertion not controlled by medications), unstable angina, acute myocardial infarction requiring surgical revascularisation, or asymptomatic but high-risk coronary anatomy. Specific anatomical patterns where CABG is preferred over PCI by international guidelines (ACC/AHA, ESC) include left main coronary artery disease (stenosis of the vessel supplying two-thirds of the heart), three-vessel coronary disease with impaired left ventricular function, complex coronary lesions (chronic total occlusions, long diffuse disease, heavily calcified vessels) unsuitable for stenting, and diabetes with multi-vessel disease.

CABG is also performed in specific emergency settings: patients presenting with cardiogenic shock due to acute MI who have complex coronary anatomy unsuitable for PCI, patients with mechanical complications of MI (ventricular septal rupture, papillary muscle rupture), and patients with failed PCI requiring emergency surgical revascularisation. Redo CABG (repeat bypass surgery) is performed for patients whose previous grafts have failed and who have exhausted other revascularisation options.

The decision to recommend CABG versus PCI versus medical therapy is made by a multidisciplinary Heart Team comprising an interventional cardiologist and a cardiac surgeon, with the patient's full participation in informed decision-making. CABG is preferred for anatomically complex disease as quantified by the SYNTAX score (a tool measuring coronary complexity) — high SYNTAX scores (above 22 to 32) favour CABG, as PCI in complex disease has significantly higher rates of repeat revascularisation. Diabetic patients with multi-vessel disease receive particular benefit from CABG, as demonstrated in the FREEDOM trial (CABG vs PCI in diabetic multi-vessel disease), showing superior survival with surgery.

Contraindications to elective CABG include terminal illness with limited life expectancy, prohibitive surgical risk from severe comorbidities (Society of Thoracic Surgeons risk score calculation guides this), coronary anatomy that makes adequate revascularisation unlikely (diffusely diseased small vessels with poor distal targets), and patient refusal after thorough informed consent discussion. Frailty assessment tools are increasingly used to identify patients who may not tolerate conventional CABG but might benefit from off-pump or minimally invasive alternatives.

Conventional CABG with cardiopulmonary bypass (on-pump CABG) remains the most common technique, providing a still, bloodless operative field for precise distal anastomoses. The LIMA is the preferred conduit for the left anterior descending artery (LAD) — the most critical coronary vessel — as LIMA-LAD grafts have 90% 10-year patency versus 50 to 60% for saphenous vein grafts. Total arterial revascularisation (using bilateral mammary arteries and radial artery grafts exclusively, avoiding vein grafts) is associated with superior long-term outcomes but is technically more demanding.

Off-pump CABG (OPCAB) performs bypass surgery on the beating heart without cardiopulmonary bypass using mechanical stabilisers, eliminating the systemic inflammatory response and neurological complications associated with the bypass machine. OPCAB is preferred for patients at high risk of bypass-related complications (aortic atherosclerosis, renal failure, severe pulmonary disease). Minimally invasive direct coronary artery bypass (MIDCAB) uses a small left thoracotomy rather than sternotomy for single- or two-vessel bypass, particularly for LIMA-LAD grafting, significantly reducing recovery time. Hybrid revascularisation combines MIDCAB (for LIMA-LAD bypass) with PCI stenting of non-LAD vessels, offering the survival benefit of arterial LAD grafting with the less invasive approach of stenting for other vessels. Hybrid coronary revascularisation — combining MIDCAB (minimally invasive CABG) for LIMA-to-LAD anastomosis with PCI for other vessels — is an option when conventional CABG carries excessive risk, preserving the benefits of the LIMA-to-LAD graft while treating other vessels percutaneously. Cardiopulmonary bypass management including temperature, flow rates, and haematocrit is individualised to optimise neurological and renal outcomes.

CABG provides highly durable coronary revascularisation. The LIMA-LAD graft has 90% patency at 10 years, compared with 50 to 60% for saphenous vein grafts and approximately 50% for coronary stents at 5 years in complex disease. Complete revascularisation of all ischaemic territories improves left ventricular function, reduces angina burden (complete angina relief in 85 to 90% of patients at one year), and improves exercise capacity. Long-term survival benefit is demonstrated in multiple trials for three-vessel disease, left main disease, and diabetic multi-vessel disease.

In the SYNTAX trial — the landmark comparison of CABG versus PCI for complex CAD — CABG achieved significantly better five-year outcomes including lower rates of death, myocardial infarction, stroke, and repeat revascularisation for high-complexity (high-SYNTAX score) disease. The FREEDOM trial demonstrated 5-year survival advantage for CABG over PCI in diabetic patients with multi-vessel disease. Cardiac rehabilitation after CABG, including supervised exercise and cardiac risk factor modification, further improves long-term outcomes with a 36% reduction in cardiac mortality demonstrated in meta-analyses.

CABG is a major cardiac surgery with procedural risks that must be weighed against the long-term benefits for each individual patient. The STS (Society of Thoracic Surgeons) calculator estimates 30-day operative mortality based on patient-specific risk factors — for elective isolated CABG in typical patients, operative mortality is 1 to 2% at high-volume centres. For emergency or re-do CABG, mortality is higher (5 to 15%).

Neurological complications include stroke (1 to 2%), cognitive decline (more common after on-pump than off-pump CABG, usually temporary), and rare severe neurological injury. Perioperative myocardial infarction from graft failure or technical issues occurs in approximately 1 to 3% of cases. Wound complications include deep sternal wound infection (1 to 2%, treated with debridement and flap closure), superficial wound infection, and leg wound complications from saphenous vein harvest (typically minor). Arrhythmias — particularly atrial fibrillation — occur in 20 to 40% of post-CABG patients and are usually self-limiting but require anticoagulation. Renal impairment requiring temporary dialysis affects approximately 1 to 3% of patients. Graft failure (vein graft occlusion in the first month — often from technical issues or hypercoagulable state) is uncommon but requires prompt investigation.

Hospital recovery after CABG typically requires five to seven days. The first 24 to 48 hours are spent in the cardiac intensive care unit for haemodynamic stabilisation and ventilator weaning. Chest drains are removed at 24 to 48 hours when drainage is minimal. Sternal wound care and activity restrictions to protect the healing sternum — no heavy lifting for six to eight weeks — are essential.

Cardiac rehabilitation beginning two to four weeks after surgery significantly improves recovery, exercise capacity, and long-term outcomes. Return to driving (where legally permitted) is typically four to six weeks post-operatively. Return to sedentary work is possible at six to eight weeks; physical work at two to three months. Sexual activity can usually be resumed at six to eight weeks. Long-term medications after CABG include daily aspirin (lifelong), statin therapy (lifelong), beta-blockers (typically for one year post-operatively), and ACE inhibitors for patients with reduced LV function. Annual cardiological review including stress testing assesses graft function and recurrence of symptoms.

CABG surgery in the United States costs $70,000 to $200,000 including surgeon fees, anaesthesia, operating room, ICU care, and post-operative hospitalisation. Insurance coverage varies — Medicare and most commercial insurers cover medically indicated CABG. The total cost including cardiac rehabilitation, medications, and follow-up over the first year can approach $200,000 to $300,000 in the US private healthcare system.

Medical tourism for CABG is one of the most common procedures sought abroad, given the dramatic cost differentials. JCI-accredited cardiac surgery centres in India — such as Fortis Escorts, Narayana Hrudayalaya (the world's highest-volume cardiac surgery centre), Apollo Hospitals, and Medanta — perform CABG with outcomes comparable to leading Western institutions. CABG at a premier Indian cardiac centre costs $5,000 to $10,000 all-inclusive — representing savings of 85 to 95% compared with US private rates. Thailand (Bumrungrad, Bangkok Heart Hospital) and Turkey (Memorial, Florence Nightingale hospitals) offer CABG for $12,000 to $25,000. International patients benefit from savings while receiving care from surgeons performing hundreds of CABG operations annually.

Percutaneous coronary intervention (PCI) with drug-eluting stents is the catheter-based alternative to CABG for coronary revascularisation. PCI involves threading a catheter through the femoral or radial artery to the coronary arteries, inflating a balloon to open the blockage, and deploying a metallic stent to maintain patency. PCI is faster, requires no general anaesthesia or sternotomy, and has shorter recovery (one to three days versus five to seven), but is inferior to CABG for complex multi-vessel disease (SYNTAX score greater than 22), left main disease, diabetic multi-vessel disease, and situations where complete revascularisation is unlikely with stenting alone.

Optimal medical therapy (OMT) — aggressive pharmacological management of coronary artery disease with statins, ACE inhibitors, beta-blockers, aspirin, and lifestyle modification — is an alternative to revascularisation for some patients with stable angina and less severe coronary disease. The ISCHEMIA trial demonstrated that OMT alone is not inferior to revascularisation for many patients with stable ischaemic heart disease, shifting the paradigm toward reserving CABG primarily for patients with anatomically severe disease, poor LV function, or refractory symptoms despite optimal medical management.